Erik R Dubberke
Overview
Explore the profile of Erik R Dubberke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
189
Citations
5390
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fishbein S, DeVeaux A, Khanna S, Ferreiro A, Liao J, Agee W, et al.
Cell Host Microbe
. 2024 Dec;
33(1):30-41.e6.
PMID: 39731916
Gastrointestinal colonization by Clostridioides difficile is common in healthcare settings and ranges in presentation from asymptomatic carriage to lethal C. difficile infection (CDI). We used a systems biology approach to...
2.
Baghdadi J, Wessel M, Dubberke E, Lydecker A, Claeys K, Alonso C, et al.
Antimicrob Steward Healthc Epidemiol
. 2024 Oct;
4(1):e168.
PMID: 39411667
Background: infection (CDI) may be misdiagnosed if testing is performed in the absence of signs or symptoms of disease. This study sought to support appropriate testing by estimating the impact...
3.
Dubberke E, Li Q, Obi E, Turzhitsky V, Siddiqui F, Nathanson B
Open Forum Infect Dis
. 2024 Oct;
11(10):ofae524.
PMID: 39355263
Background: The 2021 update to the Infectious Diseases Society of America infection (CDI) guidelines recommended fidaxomicin as the preferred treatment over vancomycin for patients with initial and recurrent CDI. Few...
4.
Feuerstadt P, Chopra T, Knapple W, Van Hise N, Dubberke E, Baggott B, et al.
Clin Infect Dis
. 2024 Aug;
80(1):43-51.
PMID: 39180326
Background: The aim of this study was to evaluate the safety and efficacy of fecal microbiota, live-jslm (RBL; REBYOTA)-the first single-dose, broad consortia microbiota-based live biotherapeutic approved by the US...
5.
Donskey C, Dubberke E, Klein N, Liles E, Szymkowiak K, Wilcox M, et al.
Clin Infect Dis
. 2024 Aug;
79(6):1503-1511.
PMID: 39180325
Background: Clostridioides difficile infection (CDI) causes substantial mortality and healthcare burden. We assessed the detoxified toxin-A/B PF-06425090 vaccine for primary CDI prevention. Methods: This phase 3 observer-blinded study randomized (1:1)...
6.
Fishbein S, DeVeaux A, Khanna S, Ferreiro A, Liao J, Agee W, et al.
bioRxiv
. 2024 Jul;
PMID: 39026847
Gastrointestinal colonization by is common in healthcare settings and ranges in clinical presentation from asymptomatic carriage to lethal infection (CDI). We used a systems biology approach to investigate why patients...
7.
Choi J, Thanert R, Reske K, Nickel K, Olsen M, Hink T, et al.
EClinicalMedicine
. 2024 May;
71:102490.
PMID: 38813445
Background: Urinary tract infections (UTI) affect approximately 250 million people annually worldwide. Patients often experience a cycle of antimicrobial treatment and recurrent UTI (rUTI) that is thought to be facilitated...
8.
Newcomer E, Fishbein S, Zhang K, Hink T, Reske K, Cass C, et al.
mBio
. 2024 Feb;
15(3):e0330023.
PMID: 38329369
Importance: infection remains a leading cause of hospital-associated diarrhea, despite increased antibiotic stewardship and transmission prevention strategies. This suggests a changing genomic landscape of . Our study provides insight into...
9.
Okhuysen P, Ramesh M, Louie T, Kiknadze N, Torre-Cisneros J, de Oliveira C, et al.
Clin Infect Dis
. 2024 Feb;
78(6):1462-1472.
PMID: 38305378
Background: Exposure to antibiotics predisposes to dysbiosis and Clostridioides difficile infection (CDI) that can be severe, recurrent (rCDI), and life-threatening. Nonselective drugs that treat CDI and perpetuate dysbiosis are associated...
10.
Brown D, Olsen M, Keller M, Stwalley D, Tipping A, Yu H, et al.
Infect Control Hosp Epidemiol
. 2024 Jan;
45(5):681-683.
PMID: 38268338
Using a life tables approach with 2011-2017 claims data, we calculated lifetime risks of infection (CDI) beginning at age 18 years. The lifetime CDI risk rates were 32% in female...